IP Library › Granted Patent US 8,829,052
Granted Patent B2
US 8,829,052 · App. 13/243,368 · Granted Sep 9, 2014

Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,829,052
App. No.
13/243,368
Granted
Sep 9, 2014
Kind
B2
Abstract

This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

Claims (24)

1. A method for the treatment of a proliferative disease in an individual or a method for inhibiting tumor size increase, reducing the size of a tumor, or reducing tumor proliferation in an individual, wherein said treatment does not include prophylaxis,

comprising administering to said individual an effective amount of one of the following compounds or a pharmaceutically acceptable salt, ester, or tautomer thereof:

2. A method according to claim 1 , wherein one of the following compounds, or a pharmaceutically acceptable salt thereof is administered to said individual

3. A method according to claim 1 , further comprising administering radiation therapy, chemotherapy or a combination of both.

4. A method according to claim 1 , further comprising administering at least one additional therapeutic agent.

5. A method according to claim 1 , wherein said individual is a mammal.

6. A method according to claim 1 , wherein said mammal is human.

7. A method according to claim 1 , wherein a proliferative disease is treated, which is, psoriasis, restenosis, an autoimmune disease, or atherosclerosis.

8. A method according to claim 1 , wherein a proliferative disease is treated, which is cancer, which cancer is brain cancer, breast cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, colorectal cancer, leukemia, myeloid leukemia, glioblastoma, follicular lymphona, pre-B acute leukemia, chronic lymphocytic B-leukemia, mesothelioma or small cell line cancer.

9. A method according to claim 1 , which is for inhibiting tumor size increase or reducing the size of a tumor, wherein said tumor occurs in the brain, breast, lung, ovaries, pancreas, prostate, kidney, colon or rectum.

10. A method according to claim 1 , wherein a proliferative disease is treated, which is acute myeloid leukemia or multiple myeloma.

11. A method according to claim 1 , wherein a proliferative disease is treated, which is breast cancer.

12. A method according to claim 1 , wherein a proliferative disease is treated, which is thyroid cancer.

13. A method according to claim 1 , wherein a proliferative disease is treated, which is colon cancer.

14. A method according to claim 1 , wherein a proliferative disease is treated, which is liver cancer.

15. A method according to claim 1 , wherein a proliferative disease is treated, which is non-small-cell lung cancer.

16. A method according to claim 1 , wherein a proliferative disease is treated, which is melanoma.

17. A method according to claim 1 , wherein a proliferative disease is treated, which is pancreatic cancer.

18. A method according to claim 1 , wherein a proliferative disease is treated, which is ovarian cancer.

19. A method according to claim 1 , wherein a proliferative disease is treated, which is hepatocellular cancer.

20. A method according to claim 1 , wherein a proliferative disease is treated, which is biliary cancer.

21. A method according to claim 1 , wherein a proliferative disease is treated, which is renal cancer.

22. A method according to claim 1 , wherein a proliferative disease is treated, which is colorectal cancer.

23. A method according to claim 1 , wherein one of the following compounds, or a pharmaceutically acceptable salt thereof is administered to said individual